Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 26 Sarcoma 16 Neoplasm Metastasis 12 Carcinoma, Non-Small-Cell Lung 9 Ovarian Neoplasms 8 Breast Neoplasms 8 Recurrence 6 Neoplasms 5 Melanoma 4 Liposarcoma 4 Leiomyosarcoma 4 Glioblastoma 4 Fallopian Tube Neoplasms 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Small Cell Lung Carcinoma 3 Prostatic Neoplasms 3 Neuroendocrine Tumors 3 Lung Neoplasms 3 Kidney Neoplasms 3 Hemangiosarcoma 3 Gastrointestinal Stromal Tumors 3 Thyroid Neoplasms 2 Thyroid Carcinoma, Anaplastic 2 Sarcoma, Synovial 2 Sarcoma, Alveolar Soft Part 2 Rhabdomyosarcoma 2 Pancreatic Neoplasms 2 Osteosarcoma 2 Gliosarcoma 2

Interventions

Nivolumab 5 olaparib 3 Specimen Handling 3 Paclitaxel 3 durvalumab 2 cediranib 2 Magnetic Resonance Spectroscopy 2 Carboplatin 2 Biopsy 2 rucaparib 1 pazopanib 1 pamiparib 1 liposomal doxorubicin 1 ceralasertib 1 capivasertib 1 cabozantinib 1 apatinib 1 Trabectedin 1 Ipilimumab 1 Immunoglobulin G 1 Gemcitabine 1 Fluid Therapy 1 Disulfides 1 Cisplatin 1 CTLA-4 Antigen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinosarcoma × pazopanib × Clear all

NCT02203760 2024-11-15

PazoDoble

North Eastern German Society of Gynaecological Oncology

Phase 2 Active not recruiting

Carcinosarcoma, Leiomyosarcoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡